2025-04-03XQuote

Source item

Investors in the health care/multiomics space seem to be missing an impending shift from “sick care” to early diagnoses and cures, championed by Robert Kennedy and new HHS talent like Scott Steele. This shift could resuscitate ROIs in the biotech space significantly.

Quoted context

These are the quoted author’s words.

FDA shakeup: Scott Steele is now acting director of CBER. Unlike his predecessors, Steele isn’t an MD — but a molecular biologist turned science policy expert with deep White House + FDA experience. He co-authored a key 2022 paper advocating agile regulatory ecosystems to accelerate innovation. This is more than a leadership change. It signals potential for a faster, more adaptive CBER — one that can match the speed of innovation in biologics, cell & gene therapies, and regenerative medicine. If implemented right, Steele’s philosophy could enable: — Faster approvals of novel platforms — Smarter, risk-adjusted oversight — A shift from reactive to curative therapies Big win for patients and investors: shorter time to market = higher ROI. The question now is: will Steele's agile vision survive political headwinds and entrenched regulatory inertia?
Ovid_ARK ↗